

## Alternatives To Animal Experimentation



June 6-7, 2023 • Biocitech Paris-Romainville

### GOLD SPONSOR



### SILVER SPONSORS



### BRONZE SPONSORS



### Day One: Tuesday June 6<sup>th</sup>

9h30 Welcome Coffee and registration (Auditorium Pasteur, Biocitech)

10h00-12h00 Pre-conference technology workshops and demos (Conference foyer)

**Important: Access to workshops / demos is exclusively limited to participants duly registered to the plenary conference and should be booked separately**

- **Workshop 1:** MatTek tissue models
- **Workshop 2:** NETRI Organs-on-chip architectures and High-throughput microfluidics platform NeoBento
- **Workshop 3:** ALTERTOx "TATABox" edutainment game meant to open a conversation about NAMs and validation process in a fun and convivial environment.

12h00 Buffet lunch for workshops attendees

13h30 Welcome Coffee and registration (Auditorium Pasteur, Biocitech)

**14h00-15h00 Plenary Conference starts - Welcome and Keynote**

14h00 Welcome by Conference organizers

Sylvio BENGIO, Adebitech / Christophe DINI, Oroxcell

14h15 Keynote lectures

Amy CLIPPINGER, PETA Science Consortium International e.V. (USA)

**15h00-18h20 Session 1 - INNOVATIONS: New Alternative Methods (NAMs) and new approaches to reduce animal testing.**

*Session chair: Nico FORRAZ, CTIBiotech*

15h00 Patricia MARTIN, VIBIOSPHEN

*Apical out lung organoids as a relevant tool to study respiratory diseases.*

15h20 Thibault HONEGGER, NETRI

*Brain-on-chip devices/ integration of different technologies into the same chip*

15h40 Sinan KARABOGA / Stéphane GÉGOUT, HARMONIC PHARMA

*QSAR assisted Predictive toxicology and animal experimentation replacement.*

16h00 Yuri DANCİK, CERTARA (USA / UK)

*In vitro-in vivo extrapolation of dermal absorption of topically applied drug products using physiologically based pharmacokinetic (PBPK) modeling.*

16h20 Coffee break

17h00 Nicolas VIOLLE, ETAP-LAB

*Reducing animal use in efficacy studies of complex neurological diseases: good and bad news*

17h20 Gregory LEMKINE, WATCHFROG LABORATORIES

*New Alternative Methods (NAMs) for endocrine disruptors testing lessons learnt from applying OECD guidelines.*

17h40 Jérôme CARON, CYPRIO

*Encapsulated spheroids applications*

18h00 Short presentations

18h00 Leslie COUEDELO, ITERG

*Nutrition – alternative to in vivo model*

18h10 Sébastien RENOUF, PathoQuest

*RNA Next-Generation Sequencing transcriptomics analysis: an alternative validated method to replace animal in vivo tests for assessing the viral safety of cell based Biologics*

18h20-19h30

**FLASH CORPORATE PRESENTATIONS**

**Altertox**, Valentin SALAMONE

**CTIBiotech**, Nico FORRAZ

**Episkin**, Christelle VIDEAU

**Epithelix**, Samuel CONSTANT

**Fluigent**, Aurélie MORYTKO

**Harmonic Pharma**, Aurélien STAB

**MatTek**, Miroslav KANĎÁR

**NETRI**, Thibault HONEGGER

**Oroxcell**, Christophe DINI

**PerkinElmer/Revvity**, Julian BURSZTYKA

**SABEU**, Karina CUANALO-CONTRERAS

**Vibiosphen**, Patricia MARTIN



**19h30-20h30**  
**COCKTAIL**



## Day Two: Wednesday June 7th

9h00 Welcome Coffee (Auditorium Pasteur, Biocitech)

### 9h30-11h00 Session 2 - Pharmaceutical industry applications

Session chairs: **Corinne Guicheney Galapagos** / **Christophe DINI, Oroxcell**

- 9h30 **Valérie CZEPCZOR, SANOFI**  
*in vitro ADME, our Challenges to Support Research Projects, how can we better predict cerebral or tumor penetration and therapeutic protein PK parameters, with the support of 3D cultures, microfluidic systems and “new” in vitro matrices?*
- 9h50 **Yunhai CUI, BOEHRINGER INGELHEIM GmbH (Germany)**  
*Epilntestinal microtissues as a model for Firstpass drug metabolism and transport*
- 10h10 **Jan-Lund OTTESEN, Novo Nordisk (Denmark)**  
*A future without laboratory animals – what does it take?*
- 10h30 **Samuel CONSTANT, EPITHELIX**  
*Models in infectiology and respiratory diseases: OECD validation, safety and efficacy*
- 10h50 Coffee break

### 11h05-12h05 Session 3 - Chemical industries, medical devices and Cosmetics

Session chair: **Christian PELLEVOISIN, MatTek**

- 11h05 **Thomas LÉOPOLD, FRANCE CHIMIE**  
*Review of the evolution of REACH requirements and role of the NAM (new alternative methods)*
- 11h25 **Peter CORNELIS, NELSON LABS (Belgium)**  
*The Biocompatrail: a challenging hike towards animal-free testing of Medical Devices*
- 11h45 **Colin MC GUCKIN, CTIBiotech**  
*Bioimpedance-connected and vascularized 3D bioprinted human skin chip for high throughput efficacy testing*

### 12h05-13h05 FLASH SCIENTIFICS POSTERS

- 12h05 **Éric ANDRES, Oroxcell**  
*Skin sensitization and photosensitization evaluation through LC-MS/MS, HRMS and 3D reconstructed tissue approaches : An integrative evaluation strategy addressing the mixtures challenge*
- 12h10 **Mendy BOUVERET, Epithelix**  
*Novel fully primary human airway epithelium-alveolar macrophages in vitro co-cultures models to study host pathogen interactions*
- 12h15 **Karina CUANALO-CONTRERAS, SABEU**  
*Membrane technology for tissue engineering*
- 12h00 **Alan DUBOIS, GIS FC3R**  
*Mapping of Replacement in France based on the projects submitted for the second call for projects of the FC3R*
- 12h25 **Edith FILAIRE, ICARE Laboratoire**  
*Innovative in vitro 3D skin model for safety assessment: a case report for the skin sensitization*
- 12h30 **Laure GEOFFROY, INERIS**  
*Francopa’s point of view: where are we with the use of NAMs for regulatory purpose?*

- 12h35 **Christina LE TANNO**, **UMR1011 - Récepteurs Nucléaires - Maladies Métaboliques et Cardiovasculaires**  
*Microfluidic pump systems: a way to replace animal models to study aortic endothelial cells response and viability to high shear stress*
- 12h40 **Astrid CAPELLO**, **Galapagos**  
*Assessing compounds using an animal-free testing strategy*
- 12h45 **Nicolas GAUDENZIO**, **Genoskin**  
*The Hyposkin® platform: a unique framework to decipher the early steps of human immune response to vaccines at the site of injection*
- 12h50 **Elodie OLIVIER**, **Laboratoire de Chimie-Toxicologie Analytique et Cellulaire, Faculté de Pharmacie, Université Paris Cité**  
*Hormonal impact of bisphenols A, F and S in human placental cells*
- 13h55 **Benoit CUDENNEC**, **UMRT BioEcoAgro 1158 Univ. Lille**  
*In vitro and in vivo comparison of the DPP-IV inhibitory activity of dietary proteins from different origins after gastrointestinal digestion*
- 13h00 *Buffet lunch, networking*

#### 14h15-15h15 Session 4 - Nutrition

*Session chair: Rozenn RAVALLEC, Transborder INRAe BioEcoAgro Unit, Lille University*

- 14h15 **Jonna KOPER**, **LESAFFRE**  
*Intestinal simulators in the 3R context*
- 14h35 **Anthony TREIZEBRE**, **LILLE UNIVERSITY**  
*Organs-on-Chips: a new technological revolution for Food Safety and health impact*
- 14h55 **Noémie DANIEL**, **SYMRISE**  
*Complementary animal and advanced in vitro models to investigate the role of polyphenols and gut microbiota-host relationship in metabolic diseases.*
- 15h15 *Coffee break*

15h30-16h45

## GENERAL TRANSDISCIPLINARY ROUND TABLE and CONFERENCE CONCLUSIONS

With speakers and participants to the Conference

Quentin BAILLEUL, [Roquette](#)

Nabil BOSCO, [Lesaffre](#)

Jeffrey BROWN, [PETA Science Consortium International e.V.](#)

Pauline DHORDAIN, [Ingredia](#)

Christophe DINI, [Oroxcell](#)

Nico FORRAZ, [CTIBiotech](#)

Corinne GUICHENEY, [Galapagos](#)

Thomas LÉOPOLD, [FRANCE CHIMIE](#)

Jan-Lund OTTESEN, [Novo Nordisk \(Denmark\)](#)

Christian PELLEVOISIN, [MatTek](#)

Rozenn RAVALLEC, [Transborder INRAe BioEcoAgro Unit, Lille University](#)

*The following topics (list not limitative) will be discussed during the round table  
between speakers, chairpersons and the audience:*

- Biggest recent highlights of NAMs acceptance in various industries
- Scientific validation vs Regulatory authorities' acceptance
- Do historically regulatory toxicological endpoints need to be revisited?
- Difference between geographies (Europe, USA, Asia)
- What is the economic impact (cost reduction) of NAMs adoption?
- Bridges and differences between NAMs adoption across various industry sectors
- Specificities in nutrition studies
- What further progress animal based CROs need to face in the next years?
- Impact of Corporate Social Responsibility